Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study
Open Access
- 1 June 2020
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 201 (11), 1372-1379
- https://doi.org/10.1164/rccm.202003-0543oc
Abstract
Background: The global death toll from COVID-19 virus exceeds 21000. The risk factors for death were attributed to advanced age and co-morbidities, but haven't been accurately defined. Objectives: To report the clinical features of 85 fatal cases with COVID-19 in two hospitals in Wuhan. Method: Medical records of 85 fatal cases of COVID-19 between January 9 and February 15, 2020 were collected. Information recorded included medical history, exposure history, comorbidities, symptoms, laboratory findings, CT scans and clinical management. Measurements and Main Results: The median age of the patients was 65.8 years and 72.9% were male. Common symptoms were fever (78 [91.8%]), shortness of breath (50 [58.8%]), fatigue (50 [58.8%]), dyspnea (60 [70.6%]). Hypertension, diabetes and coronary heart disease were the most common comorbidities. Notably, 81.2% patients had very low eosinophil counts at admission. Complications included respiratory failure (80 [94.1%]), shock (69 [81.2%]), ARDS (63 [74.1%]), arrhythmia (51 [60%]), etc. Most patients received antibiotic (77 [90.6%]), antiviral (78 [91.8%]) and glucocorticoids (65 [76.5%]) treatments. 38 patients [44.7%] and 33 [38.8%] received intravenous immunoglobulin and interferon α2b respectively. Conclusions: In this depictive study of 85 fatal cases of COVID-19, most cases were male aged over 50 years old with noncommunicable chronic diseases. The majority of the patients died of multiple organ failure. Early onset of shortness of breath may be used as an observational symptom for COVID-19 exacerbations. Eosinophilopenia may indicate a poor prognosis. The combination of anti-microbial drugs did not offer considerable benefit to the outcome of this group of patients. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords
This publication has 23 references indexed in Scilit:
- The Middle East Respiratory Syndrome (MERS)Infectious Disease Clinics of North America, 2019
- Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto AreaJAMA, 2003
- A Major Outbreak of Severe Acute Respiratory Syndrome in Hong KongThe New England Journal of Medicine, 2003
- Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation studyThorax, 2003
- Mechanisms of eosinophil-associated inflammationJournal of Allergy and Clinical Immunology, 2000
- CD8 T Cells Are Essential in the Development of Respiratory Syncytial Virus-Induced Lung Eosinophilia and Airway HyperresponsivenessThe Journal of Immunology, 1999
- IL-5 and Eosinophils Are Essential for the Development of Airway Hyperresponsiveness Following Acute Respiratory Syncytial Virus InfectionThe Journal of Immunology, 1999
- Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen.JCI Insight, 1997
- Structure and chromosome localization of the human eosinophil-derived neurotoxin and eosinophil cationic protein genes: Evidence for intronless coding sequences in the ribonuclease gene superfamilyGenomics, 1990
- Eosinopenia of Acute InfectionJCI Insight, 1980